ProKidney Corp.
PROK
$0.09
Change (1 day)
$4.44
Year High
$1.18
Year Low
Categories
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Earnings for ProKidney Corp. (PROK)
Earnings in 2023 (TTM): $-129,451,000
According to ProKidney Corp.'s latest financial reports the company's current earnings (TTM) are $-129,451,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of ProKidney Corp.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-129,451,000 | $-35,468,000 |
| 2022 | $-147,239,000 | $-148,135,000 |
| 2021 | $-55,108,000 | $-55,146,000 |
| 2020 | $-26,981,000 | $-26,749,000 |
| 2019 | $-79,254,000 | $-79,615,000 |